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Abstract
Aneuploidy refers to karyotypic abnormalities characterized by gain or loss of individual
chromosomes. This condition is associated with disease and death in all organisms in which it has
been studied. We have characterized the effects of aneuploidy on yeast and primary mouse cells
and found aneuploidy to be detrimental at the cellular level. Furthermore, we find that aneuploid
cells exhibit phenotypes consistent with increased energy need and proteotoxic stress. These
observations together with the finding that the additional chromosomes found in aneuploid cells
are active lead us to propose that aneuploidy causes an increased burden on protein synthesis and
protein quality control pathways and so induces an aneuploidy stress response.
Alterations in chromosome number that are not a multiple of the haploid complement are
called aneuploidies. The effects of such karyotypic changes on human health are profound.
Aneuploidy is the leading cause of miscarriages and mental retardation and a key
characteristic of cancer. More than 90% of all solid human tumors are aneuploid.
Determining how aneuploidy affects cell physiology is therefore critical for understanding
the principles underlying many human diseases.
Aneuploidy differs from polyploidy, in which cells harbor a multiple of their haploid
karyotype. Polyploidy is well tolerated on both the cellular and organismal level and is part
of the normal developmental program in some tissues. In contrast, autosomal aneuploidy is
associated with severe abnormalities and death in all organisms analyzed (reviewed in
(Torres et al. 2008; Williams and Amon 2009). In budding and fission yeast aneuploidy
leads to cell proliferation defects (Niwa et al. 2006; Torres et al. 2007). In flies, with the
exception of chromosome 4, all whole-chromosome trisomies and monosomies are lethal
(Lindsley et al. 1972). Similar results are observed in worms where all trisomies and
monosomies are inviable (Hodgkin 2005). In the mouse all monosomies and all trisomies,
except for trisomy 19, are embryonic lethal. In humans, all whole-chromosome aneuploidies
except trisomy 13, 18, or 21 result in embryonic lethality. Even these viable trisomies
display severe abnormalities. Trisomy 13 or 18 individuals die within the first few months of
life and exhibit developmental abnormalities such as cardiovascular and cranio-facial
defects, developmental abnormalities of the nervous system as well as growth retardation
(Moerman et al. 1988; Lin et al. 2006). These phenotypes are also seen in the only viable
human trisomy, trisomy 21 (Antonarakis et al. 2004).
At the organismal level aneuploidy is highly detrimental, yet, at the cellular level,
aneuploidy is associated with cancer; a disease characterized by high proliferative potential.
These findings raise an interesting conundrum. How is it possible that a single extra
chromosome causes developmental defects characterized by growth retardation, yet in the
context of cancer, cells with high proliferative potential nevertheless have severe karyotypic
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abnormalities? It is possible that developmental programs are sensitive to gene copy number
changes but cell proliferation is not. For example, copy number imbalances in genes critical
for the formation of an essential organ or tissue could lead to malformation thereof and
hence death. In contrast, at the cellular level, maintenance of a stable karyotype is perhaps
not important as long as each cell has one copy of each chromosome. An alternative
hypothesis (that our studies indicate to be the correct one) is that aneuploidy is also
detrimental at the cellular level but cancer cells have acquired the ability to overcome the
adverse effects of aneuploidy to take advantage of potentially beneficial effects of the
condition. To distinguish between these possibilities and to understand the contribution of
aneuploidy to tumorigenesis, we thought it was important to determine the effects of
aneuploidy on the physiology of normal cells.
A set of shared phenotypes in aneuploid cells
To determine how aneuploidy affects the proliferation and physiology of normal cells, we
generated 20 strains of budding yeast, each strain bearing an extra copy of one or more of
the yeast chromosomes. These disomic yeast strains display decreased fitness relative to
wild type cells. Furthermore, we observed two classes of phenotypes. Phenotypes that are
specific for a particular aneuploid strain and traits that are shared among the different
aneuploid yeast strains. The most prominent among the shared traits are indicators of
proteotoxic stress. Aneuploid yeast strains are temperature sensitive, that is, their
proliferation is impaired at elevated temperature (37°C) relative to euploid cells. Most
aneuploid yeast cells are also hyper-sensitive to compounds that interfere with protein
synthesis, i.e., cycloheximide or hygromycin, and several strains show hyper-sensitivity
towards the proteasome inhibitor MG132. In addition, aneuploid yeast strains make less
biomass per glucose, share a common gene expression profile and exhibit cell proliferation
defects, most prominently a delay at the G1 – S phase transition (Torres et al. 2007).
The analysis of primary mouse embryonic fibroblasts (MEFs) trisomic for either
Chromosome 1, 13, 16 or 19 revealed similar results (Williams et al. 2008). Aneuploidy is
deleterious at the cellular level, causing cell proliferation defects. This is in agreement with
the finding that primary foreskin fibroblasts of trisomy 21 patients proliferate more slowly
than euploid control cells (Segal and McCoy 1974) and the observation that primary mouse
cells or human cell lines with decreased chromosome segregation fidelity show impaired
growth (Baker et al. 2004; Sotillo et al. 2007; Thompson and Compton 2008). Most
important, the aneuploid MEFs have similar properties as the disomic yeast strains;
aneuploid mouse cells too exhibit signs of increased energy need and of proteotoxic stress.
Trisomic MEFs show elevated uptake of glutamine, the major carbon source of the TCA
cycle in tissue culture cells (DeBerardinis et al. 2007; Williams et al. 2008). Levels of the
chaperone Hsp70 and of autophagy, which are indicators of proteotoxic stress, are also
increased in trisomic MEFs (Y.-C. Tang, unpubl.).
In summary, the characterization of normal cells with a defined aneuploid karyotype led to
two key findings. First, aneuploidy is detrimental at the cellular level. Second, aneuploid
cells exhibit two types of phenotypes: (1) Traits that are unique to a specific karyotypic
abnormality and (2) traits that are shared by most aneuploid yeast and mouse cells. Based on
the observation that many of the shared traits are reminiscent of cellular stresses, we
collectively call the shared phenotypes the “aneuploidy stress response”.
Our findings have important implications for how one thinks about cancer. Cancer cells
must overcome the adverse effects of aneuploidy in order to outgrow euploid cells and take
advantage of potential benefits that arise from the aneuploid condition. Furthermore, our
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results raise the interesting possibility that cancer cells are under energy and proteotoxic
stress caused by, at least in part, the aneuploid state of cancer cells.
Origins of the phenotypes shared by aneuploid cells
Which aspects of the aneuploid state are responsible for the phenotypes shared by disomic
yeast and trisomic mouse cells? Is it the additional DNA, additional transcripts and/or the
additional proteins? In budding yeast, it is clear that the phenotypes are due to the additional
transcripts and/or proteins. Introduction of artificial mammalian chromosomes similar in
size to yeast chromosomes, but not producing any yeast proteins and most likely producing
few if any mammalian transcripts and even fewer peptides/proteins in yeast, do not lead to
the phenotypes observed in strains with additional yeast chromosomes (Torres et al. 2007).
Furthermore, the severity of the shared phenotypes increases with the amount of additional
yeast DNA present in cells (Torres et al. 2007). These data together with the observation that
the genes located on the additional chromosomes are transcribed and translated indicate that
it is the proteins produced from the additional chromosomes and/or their production that
leads to the phenotypes seen in aneuploid cells.
The same is likely to be true in trisomic MEFs. The additional chromosomes are transcribed
and the degree of fitness loss in trisomic MEFs correlates with the size of the additional
chromosome and the number of transcripts that are generated (Williams et al. 2008). So how
do the active additional chromosomes cause the phenotypes we observe? In what follows,
we will consider the origins of the general aneuploidy associated phenotypes.
Origins of the proteotoxic stress
The fact that the additional chromosomes in aneuploid yeast and mouse cells are active must
mean that aneuploid cells face protein stoichiometry imbalances. The finding that aneuploid
cells exhibit phenotypes indicative of proteotoxic stress suggests that these imbalances cause
an increased burden on the protein quality control pathways. This is best illustrated when
thinking about two proteins, A and B, that function in a complex and whose genes are
located on two different chromosomes (Figure 1A). Producing and maintaining the exact
number of each subunit is regulated by protein quality control pathways, such as protein
degradation or chaperone-mediated sequestration and sometimes feedback controls that
regulate gene expression to maintain protein A and B in stoichiometric amounts. Several
such protein stoichiometry control pathways have been described. Unassembled ribosomal
subunits are rapidly degraded (elBaradi et al. 1986; Agrawal and Bowman 1987; Maicas et
al. 1988). Gene expression feedback mechanisms ensure the stoichiometry of histones and
α- and β-tubulin (Katz et al. 1990; Theodorakis and Cleveland 1992; Bachurski et al. 1994;
Gunjan and Verreault 2003; Libuda and Winston 2006). Translational control mechanisms
determine the stoichiometry of the ATP synthase subunits in the chloroplast (Drapier et al.
2007). Similar mechanisms must exist for many other protein complexes, because it is well
established that experimental inactivation of one subunit of a protein complex leads to
destabilization of the other subunits.
In aneuploid cells protein stoichiometry imbalances are greatly exaggerated (Figure 1B).
This leads to an increased burden on the protein quality control pathways. Importantly,
although the identity of the proteins whose stoichiometries are imbalanced will be different
for each aneuploid chromosome, the mechanisms whereby cells attempt to correct these
imbalances – protein degradation and chaperone mediated sequestration – are the same.
A prediction of the protein stoichiometry imbalance hypothesis is that haploid yeast cells
carrying an additional chromosome (disomes) should be more sensitive to proteotoxic stress
than diploid cells carrying an extra chromosome (trisomes) because the degree of
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stoichiometric imbalance is lower in diploid cells carrying an extra chromosome than in
haploid cells harboring an additional chromosome. To test this we compared the ability of
strains disomic for chromosome I, V, VIII, XI, XIV, XV or XVI with that of diploid cells
trisomic for the same chromosome to grow at high temperature (37°C), which causes protein
mis-folding or in the presence of the translation inhibitor cycloheximide, which causes
proliferation defects in yeast owing to ubiquitin depletion (Hanna et al. 2003). Figure 2
shows that all disomic strains that we analyzed are more sensitive to high temperature and
cycloheximide than trisomic cells. This observation is consistent with the idea that protein
stoichiometry imbalances are at least in part responsible for the sensitivity of cells to
conditions that interfere with protein turn over and folding.
How many yeast proteins engage the cell’s protein quality control pathways and gene copy
number feedback mechanisms on gene expression? Gene expression analysis in disomic
yeast cells showed that the genes located on the additional chromosome are on average
transcribed according to gene copy number. We observe an average 1.8 – 2.0 fold increase
in gene expression of genes located on the duplicated chromosome (Torres et al. 2007).
Thus, in yeast the number of genes that are regulated by feedback mechanisms that down-
regulate gene expression in response to increased gene copy-number is likely to be low. A
notable exception is the histone locus (Libuda and Winston 2006). In other organisms this
form of feedback regulation may be more prominent. Many transcriptional feedback
mechanisms have been described in plants, worms and flies (Straub and Becker 2007).
Whether aneuploid cells engage protein degradation pathways to attenuate protein
stoichiometry imbalances caused by aneuploidy is an important and eminently answerable
question. In a small-scale study of 16 proteins, we previously showed that proteins that
function in large macromolecular complexes, i.e. ribosomal subunits, are not up-regulated
according to gene copy number in disomic yeast strains (Torres et al. 2007). SILAC based
proteomic analyses of disomic yeast strains confirmed these results and suggest that between
20 – 30 % of the yeast proteome is attenuated at a posttranscriptional level in disomic yeast
strains (N. Dephoure and S. Gygi, pers. comm.). Identifying the pathways that bring about
this attenuation and determining their importance in aneuploid cells is an important question
that we must address.
Identifying the proteins which, when present in excess, are sequestered by chaperones will
be more challenging. Proteins that require chaperones for their folding in wild-type cells,
such as WD40-repeat proteins, protein kinases, membrane proteins and disulfide-containing
proteins are likely among them (Bukau et al. 2006; Caplan et al. 2007). But whether cells
use chaperone-mediated sequestration as a general mechanism to neutralize protein
stoichiometry imbalances and whether such mechanisms are important for the survival of
aneuploid cells remains to be determined.
Origins of the increased need for energy
The amount of biomass produced per glucose molecule was lower in disomic yeast cells
than in wild-type cells (Torres et al. 2007). Trisomic mouse cells take up more glutamine
(Williams et al. 2008), which represents the nitrogen and major carbon source of the TCA
cycle in tissue culture cells (DeBerardinis et al. 2007; Williams et al. 2008). Yet, mouse
cells produce less biomass suggesting that trisomic mouse cells also exhibit an increased
need for energy. From these observations, it follows that aneuploid cells use energy for
things other than producing biomass. Energy could be spent making the proteins from the
additional chromosomes rather than the proteins that are needed to increase biomass and
then neutralizing them by protein quality control mechanisms such as protein degradation. It
is worth noting that protein degradation is a costly process. It has been estimated that the
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degradation of a single protein by the proteasome requires between 300–400 ATPs
(Benaroudj et al. 2003).
Origins of the cell proliferation defect
All aneuploid yeast and primary mouse cells that we examined show cell proliferation
defects. The basis for the decreased ability of trisomic mouse cells to accumulate in culture
is not yet known but specific cell cycle defects have been identified in aneuploid yeast
strains. Most of the aneuploid yeast strains that we analyzed exhibit a G1 delay (Torres et al.
2007). A smaller number of aneuploid cells have additional cell cycle defects.
Are the cell cycle delays observed in the aneuploid cells due to a response to the aneuploid
state of the cell (i.e. elicited by the proteotoxic or energy stress) or due to the mis-regulation
of individual cell cycle proteins or both? Heat shock, for example, causes cells to delay in
G1 (Nover 1991). The proteotoxic stress or energy stress could also cause a slowing of the
cell cycle in G1 as part of an aneuploidy response mechanism. Adapting to or compensating
for various stresses may be more effective or lead to a higher survival rate when cells are in
G1. It is also possible that the excess proteins produced in the aneuploid cells engage the
protein quality control pathways of the cell thereby interfering with the timely degradation
and/or folding of key cell cycle regulators. Finally, the two -fold increase of G1 regulators in
disomic cells could interfere with cell proliferation especially the G1 – S phase transition.
The number of such copy-number sensitive cell cycle regulators genes is however likely to
be small. Only a few proteins are known that, when present in two copies, hamper cell
proliferation. The best characterized example and only gene that causes lethality when
present in two copies in the cell is the β-tubulin-encoding TUB2 gene (Schatz et al. 1988).
Other genes are known to subtly impair proliferation when present in two copies, for
example, the actin- encoding ACT1 gene or the protein phosphatase encoding CDC14 gene
(Kaizu et al. ; Liu et al. 1992). It is also formally possible that excess proteins interfere with
the production or regulation of essential cell cycle regulators. Why this would preferentially
lead to a cell cycle delay in G1 is however not obvious. Clearly, it will be necessary to
characterize the cell cycle defects of disomic yeast strains in depth as well as to design
strategies to identify all genes that impair cell proliferation when present in two copies.
Relationship between aneuploidy and cancer
Theodor Boveri was the first to raise the possibility of a link between aneuploidy and tumor
formation. Boveri speculated that some aneuploid cells could proliferate better than wild-
type cells or in ways that wild-type cells would not. Our results indicate that aneuploidy
causes a proliferative disadvantage in primary yeast and mouse cells. Is aneuploidy a
byproduct of cancer or does it promote tumorigenesis despite its adverse effect on cell
proliferation? To get at this question it is important to review the evidence for and against a
tumor-promoting role of aneuploidy.
Evidence against a role for aneuploidy in inducing tumorigenesis
Individuals carrying an extra copy of Chromosome 21 have a 50% lower probability of
developing solid tumors than individuals with the correct chromosome number (Hasle et al.
2000; Satge et al. 2003). Mice carrying segmental trisomies also exhibit a reduced incidence
of intestinal neoplasia in the sensitized APCMin genetic background (Sussan et al. 2008).
Furthermore, a mouse model in which low-level aneuploidy was induced by interfering with
the chromosome segregation machinery prevented tumor formation in most tissues and
caused tumor formation only very late in the others (Weaver et al. 2007). Perhaps the
strongest argument against a role for aneuploidy in the selection for cancer cell fitness is the
cytogenetic characterization of primary tumors. Many structural and numerical aberrations
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have been identified in solid tumors, yet relatively few are shared among specific types of
solid tumors and even between cells within a tumor (reviewed in (Albertson et al. 2003)).
Even fewer such aberrations have been shown to contribute to tumor formation (reviewed in
(Albertson et al. 2003)).
If aneuploidy does not contribute to tumorigenesis, why are solid tumors aneuploid?
Aneuploidy could be a consequence of loss of p53. Loss of function of the tumor suppressor
gene p53 leads to aneuploidy in cultured cells. The basis for p53’s role in preventing
karyotype destabilization is not fully understood but inactivation of p53 results in
tetraploidization (Bunz et al. 2002), a state that might facilitate aneuploidy. In general,
inactivation of p53 is thought to be a late event during tumorigenesis. Thus, aneuploidy
could simply be a consequence of loss of p53 that occurs late during tumorigenesis and does
not contribute to tumor development.
Evidence for a role for aneuploidy in promoting tumorigenesis
Several findings argue for aneuploidy being an early and causative event during
tumorigenesis. The observation that low grade, small adenomas and pre-malignant atypical
ductal hyperplastic cells show a low degree of aneuploidy (Bomme et al. 1998; Bomme et
al. 2001; Shih et al. 2001; Larson et al. 2006) suggests that discrete chromosome gains play
a causative role early during tumorigenesis. Furthermore, even though tumors form late in
mice carrying mutations that induce chromosome instability, they do arise with a statistically
significant increased frequency in some tissues (Michel et al. 2001; Iwanaga et al. 2007;
Jeganathan et al. 2007; Sotillo et al. 2007; Weaver et al. 2007; Baker et al. 2009). These
findings indicate that under specific circumstances, i.e. in specific tissues or during certain
developmental stages an additional copy of specific chromosomes accelerates some aspects
of tumorigenesis. For example, gaining an additional copy of an oncogene or losing a copy
of a tumor suppressor gene could promote inappropriate cell proliferation in differentiated
non-dividing tissues.
Is single chromosome aneuploidy a good model for aneuploidy in cancer?
The role of aneuploidy in tumorigenesis continues to be controversial. Single chromosomal
gains rarely occur in cancer. Instead, severe karyotypical abnormalities, involving many
chromosomes and often multiple copies of individual chromosomes are common. These
observations beg the question whether the study of disomic and trisomic cells represents a
good model for studying the role of aneuploidy in tumorigenesis. We believe that it is for the
following reasons. First, unlike genome-instability inducing mutations, the karyotypes of the
disomic and trisomic strains do not change and all cells harbor the same karyotype. Second,
important features and traits of the aneuploid state can be deduced from the analysis of
multiple single chromosomal abnormalities because phenotypes shared by cells carrying
disomies or trisomies of different identity will speak to the aneuploid condition in general.
Finally, it is important to note that in several cancers aneuploidy involving many numerical
abnormalities is seen only late during tumorigenesis; premalignant lesions or low grade
tumors show limited chromosomal gains or losses. For example, small adenomas and
atypical ductal hyperplastic cells show a low degree of loss of heterozygosity (Bomme et al.
1998; Bomme et al. 2001; Shih et al. 2001; Larson et al. 2006). Low-grade aneuploidy may
therefore exist among premalignant lesions and in early stages of tumorigenesis. Thus, we
believe that our studies of single chromosomal abnormalities contribute to our understanding
of the role of aneuploidy during tumorigenesis and complement the analyses of aneuploidy
models that rely on chromosome mis-segregation inducing mutations to generate aneuploid
cells (Baker et al. 2004; Sotillo et al. 2007; Weaver et al. 2007; Thompson and Compton
2008; Baker et al. 2009).
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A model for how aneuploidy promotes tumorigenesis
While high-grade aneuploidy may be a late stage event in the evolution of tumors and
precipitated by the loss of p53, it is quite clear that low-grade aneuploidies exist in
premalignant lesions and early stages of the disease (Bomme et al. 1998; Bomme et al.
2001; Shih et al. 2001; Larson et al. 2006). Furthermore, several mouse studies have shown
that aneuploidy-inducing mutations predispose animals for cancer (Sotillo et al. 2007;
Weaver et al. 2007; Baker et al. 2009). How can this be, given that the aneuploid state per se
impairs proliferation rather than promotes it?
We propose two, not mutually exclusive possible explanations for these observations.
Aneuploidy could cause a proliferative advantage under conditions when normal euploid
cells in the tissue do not divide (i.e. through loss of growth or G1 – S phase transition
control). In such a situation even slowly proliferating aneuploid cells will have an advantage
over euploid cells. A similar logic could apply to the ability of cells to adapt to new
environments. Aneuploidy may allow cells to migrate to distant sites and/or colonize new
niches. This “selective edge” is best summarized by the proverb: “In the land of the blind,
the one-eyed man is king.” Even if aneuploid cells proliferate slowly, when their euploid
neighbors cannot, they will eventually outcompete their euploid parents.
Aneuploidy could also promote tumorigenesis by promoting genomic instability, hence
increasing evolvability of tumors (Torres et al. 2007; Torres et al. 2008). Aneuploidy could
cause genomic instability by multiple mechanisms (Figure 3). Gene copy imbalances in
factors essential for genome duplication and segregation as well as genome maintenance
exist in aneuploid cells thereby promoting genome instability. It is also possible that the
stresses associated with the aneuploid state, the increased burden on protein quality control
mechanisms and metabolic alterations could lead to increased genomic instability by
interfering with pathways controlling genome maintenance and propagation. Precedent for
stress induced genomic instability exists in B. subtilis, E. coli, Candida albicans and mouse
fibroblasts (Edlund and Normark 1981; Mihaylova et al. 2003; Sung et al. 2003; Ponder et
al. 2005; Selmecki et al. 2006). Increased genomic instability in turn could promote the
evolution of tumors with high proliferative potential and ability to adapt to different
environmental conditions. Thus, we propose that in a rather counterintuitive manner, the
adverse properties of aneuploidy are the reasons why aneuploidy promotes tumor growth
and development. We are currently testing the hypothesis that aneuploidy promotes genomic
instability in yeast.
What’s next?
Our analysis of primary aneuploid yeast cells and trisomic MEFs led to several hypotheses
as to how the aneuploid state affects cellular physiology. Clearly, it will be necessary to
continue to characterize the effects of aneuploidy on the cell in molecular detail. Perhaps
most exciting is the prospect of identifying genetic alterations that enhance or suppress the
adverse effects of the aneuploid state. Genes that when inactivated improve the proliferative
ability of single or multiple different aneuploidies will not only provide us with an
understanding of the defects underlying the aneuploid condition but may also shed light on
the evolution of tumors. Genetic alterations that exhibit synthetic lethality with the
aneuploid state either by exaggerating the adverse effects of aneuploidy and/or interfering
with pathways essential for the survival of aneuploid cells could provide the basis for the
discovery of new tumor treatments.
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Figure 1. Protein stoichiometry imbalances associated with aneuploidy
See text for details.
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Figure 2. Sensitivity of trisomic and disomic yeast cells to high temperature and cycloheximide
Proliferative capability of disomes and trisomes in the presence of 37°C and Cycloheximide.
10-fold dilutions are shown. Strains utilized (from top): Wild type-1N (A11311), wild
type-2N (A19550), disome I (A12683), trisome I (A18345), disome V (A14479), trisome V
(A18346), disome VIII (A13628), trisome VIII (A18347), disome XI (A13771), trisome XI
(A18348), disome XIV (A13979), trisome XIV (A18349), disome XV (A12697), trisome
XV (A18350), disome XVI (A12700) and trisome XVI (A18351).
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Figure 3. A model for how aneuploidy promotes tumorigenesis
See text for details.
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